Real-World Evidence From Commercial Use of Lentiviral Gene Therapies in Hemoglobinopathies Shows Increasing Uptake and Ongoing Safety Considerations

Genetix Biotherapeutics reported updated real-world data at the 2025 American Society of Hematology (ASH) Annual Meeting describing early outcomes and implementation metrics from commercial use of two autologous ex vivo lentiviral gene addition therapies: betibeglogene autotemcel (ZYNTEGLO™) for transfusion-dependent β-thalassemia and lovotibeglogene autotemcel (LYFGENIA™) for sickle cell disease (SCD).

Across clinical trials and post-approval commercial use, more than 250 patients have now received treatment with these platforms, with follow-up extending beyond 10 years for the earliest treated cohorts. According to the company, this constitutes the largest longitudinal dataset to date for ex vivo gene therapy in hemoglobinopathies.

Commercial Uptake and Implementation Metrics

Since regulatory approval of ZYNTEGLO (August 2022) and LYFGENIA (December 2023) through mid-November 2025:

• 392 patients have enrolled for treatment
• 216 patients have initiated cell collection
• 115 patients have completed infusion

Comparative launch metrics indicated an accelerated uptake for LYFGENIA relative to the beta-thalassemia program:

• Two-fold shorter time from FDA approval to first patient enrollment
• 167% faster enrollment rates in the first post-approval quarter
• Six-fold higher number of activated qualified treatment centers during the first quarter

These gains were attributed to operational lessons carried forward from the ZYNTEGLO launch, including optimization of referral pathways and earlier activation of treatment sites.

Implementation Bottlenecks

Analysis of treatment workflows identified manufacturing capacity and apheresis logistics as key determinants of patient throughput. Delays occurred most commonly between clinical enrollment and scheduling of stem-cell collection. While most patients completed treatment following a single collection cycle, those requiring additional collections experienced extended timelines to infusion.

To address these limitations, the company reported investments in:

• Expanded manufacturing capacity to reduce scheduling lead times
• Growth of the Qualified Treatment Center network to improve collection success rates and geographic access
• Processing enhancements, including implementation of stem-cell cryopreservation, aimed at improving scheduling flexibility
• Continued enrollment and follow-up of the multicenter HGB-210 Phase 3 study evaluating lovo-cel in pediatric and adult patients with SCD

Therapeutic Mechanisms

LYFGENIA (lovotibeglogene autotemcel) utilizes lentiviral-mediated insertion of a modified β-globin gene encoding HbAT87Q, which produces hemoglobin with anti-sickling activity. Treated autologous hematopoietic stem and progenitor cells are reinfused following myeloablative conditioning. Clinical data have demonstrated reductions in vaso-occlusive events and improvements in red blood cell function in eligible patients aged ≥12 years with SCD.

ZYNTEGLO (betibeglogene autotemcel) applies the same lentiviral platform to deliver a modified β-globin gene in patients with transfusion-dependent β-thalassemia, enabling endogenous HbAT87Q production sufficient to maintain near-normal hemoglobin levels and eliminate the need for regular transfusions in many treated patients.

Safety Considerations

Both products carry established class risks associated with myeloablative conditioning and lentiviral vector integration.

Hematologic malignancies have occurred in LYFGENIA-treated patients, including cases of acute myeloid leukemia and myelodysplastic syndrome associated with earlier manufacturing protocols. Lifelong monitoring is required, including routine complete blood counts and vector integration site analysis at prescribed intervals.

Other reported risks across programs include:

• Delayed platelet engraftment, with bleeding risk until hematologic recovery
• Neutrophil engraftment failure, necessitating rescue stem-cell infusion in some cases
• Potential for insertional oncogenesis related to vector integration
• Hypersensitivity reactions to infusion components, including DMSO and dextran
• Drug-drug interactions affecting mobilization and conditioning (notably antiretrovirals, hydroxyurea, and iron chelators)
• Interference with PCR-based HIV testing, leading to false-positive results

Common Grade ≥3 adverse events included mucositis, neutropenia, thrombocytopenia, febrile neutropenia, anemia, and leukopenia. Three patient deaths were reported in early clinical development of LYFGENIA—two due to AML associated with earlier manufacturing procedures and one related to underlying disease.

Reproductive and Long-Term Monitoring Requirements

Both therapies are contraindicated during pregnancy and breastfeeding due to the use of myeloablative conditioning agents. Patients of reproductive potential must use effective contraception during treatment and for at least six months following infusion. Fertility preservation counseling is recommended prior to therapy initiation.

Patients receiving either therapy are advised to participate in long-term post-marketing surveillance programs, with follow-up durations extending at least 15 years to monitor for late-emerging oncologic events or clonal expansion.

Original PR here